CJC-1295

Mechanism (as reported)

One study investigated CJC-1295 as a long-acting GHRH analog intended to stimulate GH secretion, which in turn was associated with increases in IGF-I levels in healthy adults (PMID 16352683). Reviews also describe growth-hormone secretagogues (including CJC-1295) as activating IGF-1 signaling in the context of regenerative mechanisms discussed for orthopaedics (PMID 41490200).

Key findings (each cites a source)

• In healthy adults, a study reported that CJC-1295 produced dose-dependent increases in mean plasma GH concentrations lasting 6 days or more after a single injection, and dose-dependent increases in mean plasma IGF-I lasting 9–11 days. [PMID 16352683]
• The same study estimated CJC-1295 plasma half-life to be 5.8–8.1 days and reported that after multiple doses, mean IGF-I levels remained above baseline for up to 28 days. [PMID 16352683]
• In that healthy-adult study, no serious adverse reactions were reported and CJC-1295 was described as safe and relatively well tolerated within the study conditions. [PMID 16352683]
• A study on identification of illicit preparations reported that an unknown pharmaceutical preparation contained a 29-amino-acid peptide with a C-terminal amide, with the proposed sequence consistent with CJC-1295 (a growth-hormone-releasing peptide). [PMID 21204297]
• A detection-focused study in equine plasma reported an LC-MS/MS confirmation approach after immuno-affinity capture and tryptic digestion to identify CJC-1295, describing challenges in detecting CJC-1295-protein conjugates and reporting identification sensitivity down to 180 pg/mL in 1 mL of equine plasma. [PMID 30938069]
• A study investigating anti-doping detection reported in vitro metabolism and detection development for four larger GHRH synthetic analogs including CJC-1295, identifying metabolites and developing an LC-MS/MS method; limits of detection for target peptides were generally 1 ng/mL or less in fortified urine. [PMID 34665524]
• A narrative review described the use of peptides in orthopaedics and noted that CJC-1295 combined with ipamorelin showed improved maximum tetanic tension in a murine model with glucocorticoid-induced muscle loss, while emphasizing that the findings were limited to animal studies. [PMID 41476424]
• A narrative review on orthopaedic therapeutic peptides discussed mechanistic signaling pathways and included CJC-1295 among growth hormone secretagogues that are discussed as activating IGF-1 signaling in the context of orthopaedic relevance. [PMID 41490200]